642
Views
1
CrossRef citations to date
0
Altmetric
Original Articles

Management of gout: Primary care approach

, MBBS, MCFP(SA), MMed(Fam Med)(Medunsa) & , MBBS, FCFP(SA), MFamMed, FACRRM, FACTM, FAFP(SA)
Pages 471-477 | Received 03 Oct 2009, Accepted 09 Dec 2009, Published online: 15 Aug 2014

References

  • Sutaria S, Katbamna R, Underwood M. Effectiveness of interventions for the treatment of acute and prevention of recurrent gout—a systematic review. Rheumatology 2006; 45: 1422–31.
  • Cassim B, Mody GM, Deenadayalu VK, Hammond MG. Gout in black South Africans: a clinical and genetic study. Annals of the Rheumatic Diseases 1994; 53: 759–62.
  • Tausche A, Jansen TL, Schröder H, Bornstein SR, Aringer M, Müller-Ladner U. Gout—current diagnosis and treatment. Dtsch Arztebl Int 2009; 106(34–35): 549–55.
  • Rubenstein J, Pritzker PH. Crystal-associated arthropathies. AJR 1989; 152: 685–95.
  • Clive DM. Renal Transplant-Associated Hyperuricemia and Gout. J Am Soc Nephrol 2000; 11: 974–9.
  • Khrishnan E, Baker JF, Furst DE, Schumacher HR. Gout and the risk of myocardial infarction. Arthritis & Rheumatism 2006; 54(8): 2688–96.
  • Singh JA, Hodges JS, Toscano JP, Asch SM. Quality of care for gout in the US needs improvement. Arthritis & Rheumatism 2007; 57(5): 822–7.
  • Mikuls TR, Farrar JT, Bilker WB, Fernandes S, Saag KG. Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: results from the UK General Practice Research Database (GPRD). Rheumatology 2005; 44: 1038–42.
  • Sarawate CA, Brewer KK, Yang W, Patel PA, Schumacher HR, Saag KG, Bakst AW. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo clinic proc. 2006; 81(7): 925–34.
  • Mikuls TR, MacLean CH, Olivieri J, Patino F, Allison JJ, Farrar JT, et al. Quality of care indicators for gout management. Arthritis & Rheumatism 2004; 50(3): 937–43.
  • Chui CH. Diagnostic dilemmas in unusual presentations of gout. Australian Family Physician 2007; 36(11): 931–4.
  • Chong Y, Fong K, Thumboo J. The value of joint aspirations in the diagnosis and management of arthritis in a hospital-based rheumatology service. Annals Academy of Medicine 2007; 36(2): 106–9.
  • Eggebeen AT. Gout: An update. Am Fam Physician 2007; 76: 801–8.
  • Suresh E. Diagnosis and management of gout: a rational approach. Postgrad Med J 2005; 81: 572–9.
  • Luk AJ, Simkin PA. Epidemiology of hyperuricemia and gout. Am J Manag Care 2005; 11: S435-S442.
  • Pillinger MH, Keenan RT. Update on the management of hyperuricemia and gout. Bulletin of the NYU Hospital for joint diseases 2008; 66(3): 231–9.
  • Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006; 65: 1312–24.
  • Cannella AC, Mikuls TR. Understanding Treatments for Gout. Am J Manag Care 2005; 11: S451-S458.
  • Choi HK, Willet W, Curhan G. Coffee consumption and risk of incident gout in men: A prospective study. Arthritis & Rheumatism 2007; 56(6): 2049–55.
  • Choi, HK, Curhan G. Coffee, tea, and caffeine consumption and serum uric acid level: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2007; 57: 816–21.
  • So A. Developments in the scientific and clinical understanding of gout. Arthritis Research & Therapy 2008; 10: 221–6.
  • Rubin BR, Burton R, Navarra S, Antigua J, Londono J, Pryhuber KG, et al. Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial. Arthritis & Rheumatism 2004; 50(2): 598–606.
  • Caspi D, Lubart E, Graff E, Habot B, Yaron M, Segal R. The effect of mini-dose aspirin on renal function and uric acid handling in elderly patients. Arthritis & Rheumatism 2000; 43(1): 103–8.
  • Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL, et al. Harrison's principles of internal medicine 2008, 17th Edition, Mc Graw Hill Medical, USA: 2165–7.
  • Van Heyningen C, Watson ID. Troponin for prediction of cardiovascular collapse in acute colchicines overdose. Emerg Med J 2005: 599–600.
  • Baud FJ, Sabouraud A, Vicaut E, Lang J, Marc J, Schermann J. Brief report: Treatment of severe colchicines overdose with colchicines-specific Fab fragments. NEJM 1995; 33(10): 642–5.
  • Schumacher Jnr HR, Chen LX. The practical management of gout. Cleveland clinical journal of medicine 2008; 75: S22–5
  • Department of Health, Republic of South Africa. Standard treatment guidelines and essential drugs list (Hospital level Adults) 2006, 2nd edition, The National Department of Health, Pretoria, South Africa: 189–90.
  • Department of Health, Republic of South Africa. Standard treatment guidelines and essential drugs list (Primary health care) 2008, 4th edition, The National Department of Health, Pretoria, South Africa: 234–6.
  • Schumacher Jnr HR, Becker MA, Wortmann RL, MacDonald PA, Hunt B, Streit J, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: A 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Care & Research 2008; 59(11): 1540–8. (Abstract).
  • Becker MA, Schumacher HR, Wortmann RL, MacDonald PA, Eustace D, Palo WA, et al. Febuxostat Compared with Allopurinol in Patients with Hyperuricemia and Gout. N Engl J Med 2005; 353: 2450–61.
  • Feher MD, Hepburn AL, Hogarth MB, Ball SG, Kaye SA. Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout. Rheumatology 2003; 42: 321–5.
  • Hepburn AL, Kaye SA, Fener MD. Fenofibrate: a new treatment for hyperuricaemia and gout? Ann Rheum Dis 2001; 60: 984–92.
  • Huang H, Appel LJ, Choi MJ, Gelber AC, Charleston J, Norkus EP, et al. The effects of vitamin C supplementation on serum concentrations of uric acid: results of a randomized controlled trial. Arthritis & Rheumatism 2005; 52(6): 1843–7.
  • Sundy JS, Ganson NJ, Kelly SJ, Scarlett EL, Rehrig CD, Huang W, et al. Pharmacokinetics and Pharmacodynamics of Intravenous PEGylated Recombinant Mammalian Urate Oxidase in Patients With Refractory Gout. Arthritis & Rheumatism 2007; 56(3): 1021–8.
  • Fachinni FS. Near-Iron deficiency-induced remission of gouty arthritis. Rheumatology 2003; 42: 1550–5.
  • Terkeltaub R, Sundy JS, Schumacher HR, Murphy F, Bookbinder S, Biedermann S, et al. The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo controlled, monosequence, crossover, nonrandomised, single-blind pilot study. Ann Rheum Dis 2009; 68: 1613–7.
  • So A, De Smedt T, Revaz S, Tschopp J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Research & Therapy 2007, 9: R28.
  • Wortmann RL. The management of gout: It should be crystal clear (Editorial). J Rheumatol 2006; 33: 1921–2.